Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Tumor-Agnostic 2Thoracic 2Plasma cell 2Lymphoid 2Head & Neck 2CNS 2Other hematologic neoplasm 1Breast 1

Conditions

Vomiting 1Neoplasms 1Nausea 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Palonosetron × Lymphoid × Clear all
NCT00600353 2017-03-09

Multi-day Doses in Prevention of Nausea and Emesis

University of Kansas Medical Center

Phase 2 Completed
20 enrolled 8 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Nausea, Neoplasms

NCT01018758 2009-11-25

NHLPal

Gruppo Italiano Studio Linfomi

Phase 2 Completed
86 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡